6386-41-0

Upstream product

• 67-56-1 methanol 
• 1611-03-6 3,5-di-tert-butyl-4-hydroxyphenyl acetic acid 

Downstream Products

• 862647-45-8 bromo-(3,5-di-tert-butyl-4-hydroxy-phenyl)-acetic acid methyl ester 
• 65559-25-3 methyl 2-(3,5-di-tert-butyl-4-oxocyclohexa-2,5-dien-1-ylidene)acetate 
• 1131688-09-9 C₂₀H₃₀O₃ 
• 1620-98-0 3,5-di-t-butyl-4-hydroxybenzaldehyde 

Relevant academic research and scientific papers

Design, synthesis, and biological evaluation of bifunctional thyrointegrin inhibitors: New anti-angiogenesis analogs

Context: Inhibition of pathological angiogenesis. Objective: Obtaining new transactivator, bifunctional, thyroid antagonist, non-toxic anti-angiogenic compounds. Materials and methods: In silico drug design, synthesis in bulk and biological evaluation in chick chorioallantoic membrane (CAM) model. Results: Significant inhibition (range 6573%) at 0.252.0 g/ml doses. Discussion and conclusion: The synthesis of compounds (9), (10), and (11) incorporating long-chain moieties guanidine, urea, methyl amine and, propyl amine substitutions, respectively, into the core molecular framework of tetrac (tetraiodothyroacetic acid) were undertaken. The evaluation of the anti-angiogenic bioactivity of these compounds in the CAM model revealed no loss of activity in comparison with tetrac and XT199, which showed nearly 86% inhibition at dose levels of 1 and 0.5 g/ml, respectively, and validated the concept.

COMPOSITIONS OF DUAL THYROINTEGRIN ANTAGONISTS AND USE IN VASCULAR-ASSOCIATED DISORDERS

A dual thyrointegrin antagonist and a method for treating an angiogenesis-mediated disorder and/or a hyperthyroidism disorders by introducing the dual thyrointegrin antagonist into animals (e.g., mammals, human beings). The dual thyrointegrin antagonist includes a chemical structure having a thyroid hormone antagonist and alphavbeta3 integrin antagonist in the same molecule

Inhibitors of lipoprotein(a) assembly

Compounds of the general structure A and B were investigated for their activity as lipoprotein(a), [Lp(a)], assembly (coupling) inhibitors. SAR around the amino acid derivatives (structure A) gave compound 14-6 as a potent coupling inhibitor. Oral dosing

Polyalkylene glycol esters of hindered phenols substituted alkanoic acid

Compounds of the formula: EQU1 WHEREIN X is oxygen or sulfur, a is an integer from 2 to 6, b is an integer from 3 to 40, and R is SPC1 Wherein R1 is an alkyl group of 1 to 8 carbon atoms, R2 is hydrogen or an alkyl group of 1 to 8 carbon atoms, and X is an integer from 0 to 6 Are useful as antioxidants for organic materials normally subject to oxidative deterioration, such as polyacetals, polypropylene, and nylon, in amounts of from about 0.005 to about 5% by weight of the composition.